Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why BeiGene Stock Is Soaring This Week

TheMotleyFool

0 0

Shares of BeiGene (NASDAQ: BGNE) were soaring 17.9% higher this week as of the market close on Thursday. The big gain came after the U.S. Food and Drug Administration (FDA) approved Brukinsa as a treatment for Waldenström's macroglobulinemia (WM), a rare type of blood cancer.

The FDA approval decision was based on data from a phase 3 study that evaluated Brukinsa in a head-to-head comparison with Imbruvica, a blockbuster blood cancer drug marketed by AbbVie and Johnson & Johnson. Brukinsa outperformed Imbruvica on several fronts in this study.

Image source: Getty Images.

Source Fool.com

Like: 0

BGNE

Share